CRNX Crinetics Pharmaceuticals

Crinetics Pharmaceuticals to Participate in December Investor Conferences

Crinetics Pharmaceuticals to Participate in December Investor Conferences

SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX), today announced that company management will participate in the following conferences in the month of December. Please see additional details below:  

Evercore ISI 3rd Annual HealthCONx Conference
Date:   Thursday, December 3rd, 2020
Time:   1:00 - 1:45 pm ET in Track 1
Panel:   Easy Pills to Swallow: Oral Drugs for Large Endo Markets
Presenter:   Dr. Scott Struthers, Founder & CEO
   
Piper Sandler's 32nd Annual Healthcare Conference
Date:   Tuesday - Thursday, December 1st - 3rd, 2020
Time:   On demand
Presenter:   , Founder & CEO, and , Chief Medical Officer
Webcast:   Pre-recorded fireside chats are available for the annual on the Events section on the Company’s website as well as on the Piper Sandler conference website.

About Crinetics Pharmaceuticals 

is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate, , is an oral selective nonpeptide somatostatin receptor type 2 biased agonist for the treatment of acromegaly, an orphan disease affecting more than 25,000 people in the United States. Crinetics plans to advance paltusotine into a Phase 3 program in acromegaly and a Phase 2 trial for the treatment of carcinoid syndrome associated with NETs in 2021. The company is also developing , an oral nonpeptide somatostatin receptor type 5 (SST5) agonist for congenital hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of and other diseases of excess ACTH. All of the company’s drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company. For more information, please visit .

Contacts:

Marc Wilson

Chief Financial Officer



(858) 450-6464

Investors / Media:

Corey Davis

LifeSci Advisors



(212) 915-2577

Aline Sherwood

Scienta Communications



(312) 238-8957



EN
23/11/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Crinetics Pharmaceuticals

 PRESS RELEASE

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Fi...

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update PALSONIFY™ (Paltusotine) Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December       Operationally Seamless Phase 2/3 Study of Atumelnant for the Treatment of ACTH-Dependent Cushing's Syndrome to Initiate in the First Half of 2026       Multiple Clinical Trials Initiated for Early- and Late-Stage Candidates               Management Hosting Conference Call at 4:30 p.m. ET Today         SAN DIEGO, Feb. 26, 2026 (GLOBE...

 PRESS RELEASE

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conf...

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX), today announced that company management will participate in the following two upcoming investor conferences: TD Cowen 46th Annual Health Care Conference, Boston, MA Fireside chat on Wednesday, March 4, 2026 at 1:50 p.m. Eastern TimeWebcast link Management will be available for 1x1 meetings with investors on Wednesday, March 4, 2026 Leerink Annual Global Healthcare Conference, Miami, FL Management will be available for 1x1 meetings with i...

 PRESS RELEASE

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 ...

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, February 26 at 4:30 p.m. ET Domestic: 1 833-470-1428International: 1 646-844-6383Access Code: 027322    Webcast: Partici...

 PRESS RELEASE

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in...

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH) First in class study of an investigational ACTH receptor antagonist aims to address significant unmet need in children and adolescents with classic CAH SAN DIEGO, Jan. 22, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that the first patient has been dosed in the BALANCE-CAH Phase 2/3 trial evaluating investigational candidate atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate for the proposed treatment of classic congen...

 PRESS RELEASE

Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Und...

Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on January 10, 2026, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 37,575 shares of its common stock and granted an aggregate of 25,525 restricted stock unit (“RSU”) awards to 10 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducemen...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch